Tobias Franiel MD, Presenter: Nothing to Disclose

Lutz Luedemann PhD, Abstract Co-Author: Nothing to Disclose

Birgit Rudolph, Abstract Co-Author: Nothing to Disclose

Matthias Taupitz MD, PhD, Abstract Co-Author: Nothing to Disclose

Bernd K. Hamm MD, Abstract Co-Author: Nothing to Disclose

Dirk Beyersdorff MD, Abstract Co-Author: Nothing to Disclose

To differentiate prostate cancer from normal prostate by absolute quantification of independent pharmacokinetic parameters.

Twenty-seven patients with biopsy-proven prostate cancer (PSA, 1.4 to 16.1 ng/ml) were examined with the dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence (T1w and T2*w; temporal resolution, 1.65 s) at 1.5 Tesla using a combined endorectal/body phased-array coil. Postprocessing algorithms based on a sequential 3-compartment model were used to calculate the following pharmacokinetic parameters: perfusion, blood volume, mean transit time, delay, and dispersion. Histologic correlation was done in 23 patients who underwent prostatectomy. A pathologist marked areas of prostate cancer (n=24) and normal prostate tissue (n=21) on histologic slices corresponding to the MR imaging planes. Prostate cancer was classified as low-grade or high-grade (Gleason score ≤ 3+3 [n=9] versus ≥ 3+4 [n=15]).

Prostate cancer had higher perfusion (1.13 vs. 0.26 ml/cm3*min, p<0.001), higher blood volume (1.49 vs. 0.95%, p=0.002), and shorter mean transit time (4.17 vs. 4.40 s, p=0.042) than normal prostate tissue. Low-grade prostate cancer only had higher perfusion compared with normal prostate (1.01 vs. 0.26 ml/cm3*min, p=0.050) while high-grade cancer had higher perfusion (1.21 vs. 0.26 ml/cm3*min, p≤0.001), larger blood volume (1.44 vs. 0.95%, p=0.005), shorter mean transit time (3.55 vs. 4.40 s, p=0.019), shorter delay (10.15 vs. 13.36 s, p=0.015), and smaller dispersion (8.56 vs. 12.11 s, p=0.020). There were no statistically significant differences between low-grade and high-grade prostate cancer.

Pharmacokinetic parameters, particularly perfusion, enable differentiation of normal prostate tissue from low-grade and high-grade prostate cancer.

Pharmacokinetic parameter perfusion helps to differentiate normal prostate tissue from low-grade and high-grade prostate cancer.

Franiel, T, Luedemann, L, Rudolph, B, Taupitz, M, Hamm, B, Beyersdorff, D, Quantitative Perfusion Analysis Using Contrast-enhanced Dynamic Dual-contrast MRI: Differentiation of Normal Prostate Tissue from Low-grade and High-grade Prostate Cancer.  Radiological Society of North America 2008 Scientific Assembly and Annual Meeting, February 18 - February 20, 2008 ,Chicago IL. http://archive.rsna.org/2008/6014478.html